ALUR

Allurion is a distressed micro-cap whose core business is imploding, not merely slowing. Revenue has fallen every year since 2022 — $64.2M → $53.5M → $32.1M → $15.2M — a 76% peak-to-trough decline, with FY2025 alone down 52.6%. This is a company shrinking toward irrelevance, not a temporary dip. Gross margin is still healthy at 62.8%, but on a $15.2M revenue base it produced only $9.57M of gross profit against an operating loss of -$30.2M (a -198% operating margin), so the model is nowhere near covering its cost structure even after a 56% cut to R&D. The FY2025 net loss of -$28.8M swung sharply negative again after a narrower FY2024, and EPS of -$3.81 is being spread across a share count that ballooned 151% year-over-year — shareholders are being diluted heavily even as the equity is destroyed.

The balance sheet is the disqualifier. Stockholders' equity is -$77.2M against $93.0M of total liabilities and just $15.8M of total assets — the company owes far more than it owns, and accumulated deficit is -$251M. Cash fell 64.8% to $5.41M while operating cash flow was -$28.9M; on that run-rate the company has only a fraction of a year of liquidity and is entirely dependent on raising external capital. Current liabilities of $38.4M (up 103.8%) dwarf current assets of $12.8M, a working-capital hole that signals near-term funding stress. The 10-K's forward-looking section reads like a survival checklist: it explicitly flags the need to 'acquire sufficient sources of funding if and when needed,' 'successfully deploy our cash,' defend litigation, execute a 'reduction in force and strategic restructuring plan,' and — tellingly — to 'maintain the listing… on a national securities exchange and relist Allurion Securities on the NYSE… NYSEA, or Nasdaq CM.' That relisting language points to an exchange-compliance/delisting problem on top of the funding gap.